Indivior Scores Docs In Suboxone Product-Hopping MDL

Law360, New York (June 28, 2016, 2:45 PM EDT) -- Drug wholesalers and others accusing Indivior of product-hopping to stifle competition from generics of the Reckitt Benckiser spinoff's opiate addiction treatment Suboxone must produce downstream sales documents because they may be relevant to liability issues, a Pennsylvania federal judge ruled Tuesday.

Indivior Inc. had complained in early January that the direct purchasers turned over virtually no information in response to the company's discovery requests. U.S. Magistrate Judge Timothy R. Rice then ordered Indivior to provide more information about why the downstream information was needed, which the company did later that month, in the form of an economist's analysis.

U.S. District Judge...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS